HK1137347A1 - Method of radio-sensitizing tumors using a radio-sensitizing agent - Google Patents

Method of radio-sensitizing tumors using a radio-sensitizing agent

Info

Publication number
HK1137347A1
HK1137347A1 HK10101210.0A HK10101210A HK1137347A1 HK 1137347 A1 HK1137347 A1 HK 1137347A1 HK 10101210 A HK10101210 A HK 10101210A HK 1137347 A1 HK1137347 A1 HK 1137347A1
Authority
HK
Hong Kong
Prior art keywords
radio
sensitizing
tumors
agent
sensitizing agent
Prior art date
Application number
HK10101210.0A
Other languages
English (en)
Inventor
James L Diebold
Robert L Hudkins
Sheila J Miknyoczki
Bruce Ruggeri
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39259576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1137347(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HK1137347A1 publication Critical patent/HK1137347A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10101210.0A 2006-11-20 2010-02-04 Method of radio-sensitizing tumors using a radio-sensitizing agent HK1137347A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86003606P 2006-11-20 2006-11-20
PCT/US2007/024271 WO2008063644A1 (en) 2006-11-20 2007-11-20 Method of radio-sensitizing tumors using a radio-sensitizing agent

Publications (1)

Publication Number Publication Date
HK1137347A1 true HK1137347A1 (en) 2010-07-30

Family

ID=39259576

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10101210.0A HK1137347A1 (en) 2006-11-20 2010-02-04 Method of radio-sensitizing tumors using a radio-sensitizing agent

Country Status (18)

Country Link
US (1) US20080146556A1 (xx)
EP (1) EP2086525B1 (xx)
JP (1) JP5542444B2 (xx)
CN (1) CN101784268B (xx)
AR (1) AR063869A1 (xx)
AT (1) ATE483456T1 (xx)
AU (1) AU2007321987B2 (xx)
CA (1) CA2671517C (xx)
CL (1) CL2007003331A1 (xx)
DE (1) DE602007009717D1 (xx)
ES (1) ES2352817T3 (xx)
HK (1) HK1137347A1 (xx)
IL (1) IL198519A (xx)
MX (1) MX2009005292A (xx)
NZ (2) NZ595522A (xx)
PT (1) PT2086525E (xx)
TW (2) TWI636795B (xx)
WO (1) WO2008063644A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178852A1 (en) * 2009-08-26 2012-04-27 Cephalon Inc Novel forms of a multicyclic compound
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2015121876A1 (en) * 2014-02-14 2015-08-20 Council Of Scientific & Industrial Research Novel tricyclic compounds and preparation thereof
US9771325B2 (en) 2014-02-14 2017-09-26 Council Of Scientific & Industrial Research Tricyclic compounds and preparation thereof
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US10150772B2 (en) * 2014-11-26 2018-12-11 Cephalon, Inc. Crystalline forms of PARP inhibitors
CN104961798A (zh) * 2015-06-28 2015-10-07 杨洋 作为parp抑制剂的化合物
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
CN113952452A (zh) * 2021-11-16 2022-01-21 苏州伊瑞斯科技有限公司 一种基于碳点的肿瘤放疗增敏剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
EP1077944A1 (en) * 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
MXPA04001353A (es) * 2001-08-15 2004-10-27 Icos Corp 2h-ftalazin-1-onas y metodos para su uso.
BRPI0515567A (pt) * 2004-09-22 2008-07-29 Pfizer combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors

Also Published As

Publication number Publication date
AR063869A1 (es) 2009-02-25
AU2007321987B2 (en) 2014-01-23
TWI636795B (zh) 2018-10-01
ES2352817T3 (es) 2011-02-23
IL198519A0 (en) 2010-02-17
EP2086525A1 (en) 2009-08-12
MX2009005292A (es) 2009-08-13
TW200829276A (en) 2008-07-16
CL2007003331A1 (es) 2008-07-04
DE602007009717D1 (de) 2010-11-18
PT2086525E (pt) 2010-12-09
NZ595522A (en) 2013-04-26
JP5542444B2 (ja) 2014-07-09
CA2671517C (en) 2015-01-27
US20080146556A1 (en) 2008-06-19
CN101784268A (zh) 2010-07-21
NZ576693A (en) 2011-12-22
IL198519A (en) 2014-07-31
JP2010510312A (ja) 2010-04-02
EP2086525B1 (en) 2010-10-06
TWI519313B (zh) 2016-02-01
ATE483456T1 (de) 2010-10-15
CN101784268B (zh) 2013-06-19
WO2008063644A1 (en) 2008-05-29
AU2007321987A1 (en) 2008-05-29
TW201601762A (zh) 2016-01-16
CA2671517A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
HK1137347A1 (en) Method of radio-sensitizing tumors using a radio-sensitizing agent
IL185908A0 (en) Therapeutic agent for dyskinesia
EP1986699A4 (en) RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
EP2127671A4 (en) THERAPEUTIC AGENT AGAINST CANCER
GB0601962D0 (en) Therapeutic agents
IL197389A0 (en) Prophylactic or therapeutic agent for cancer
IL197363A0 (en) Compounds and methods for 18f labeled agents
EP2020402A4 (en) DEHYDROXYLATED FLUORINATING AGENT
EP1980237A4 (en) GELIFYING AGENT
EP2046396A4 (en) METHOD AND MEANS FOR PRODUCING 18F RAY-MARKED FLUORINATING AGENTS
IL196208A0 (en) Methods for cancer treatment using tak1 inhibitors
GB0611152D0 (en) Therapeutic agents
EP2123270A4 (en) MEANS TO IMPROVE THE IRON FLUID CHANGE
EP1862804A4 (en) METHOD FOR DIAGNOSIS OF PROSTATE CANCER
HK1110224A1 (en) Therapeutic agent for cancer
EP2062892A4 (en) AGENT ENHANCING HYPERTENSION
GB0624587D0 (en) Chelating agent
GB0619016D0 (en) Ultrasound method
EP2018873A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER
EP2222328A4 (en) PROCESS FOR THE ADMINISTRATION OF CONJUGATES
EP2030629A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
EP2083114A4 (en) FIBROUS PRODUCT PROCESSING AGENT

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191120